Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Yovine · SciRah

Researcher profile · Semantic Scholar

A. Yovine

Share profile

A. Yovine — researcher profile on SciRah

h-index: 20
Works: 57
Citations: 2,252

Most-cited papers

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial
Dong-Wan Kim, R. Mehra, D. Tan, E. Felip +17 more
2016The Lancet Oncology356 citations Open access
Semantic Scholar
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
A. Yovine, M. Riofrio, J. Blay, E. Brain +8 more
2004Journal of Clinical Oncology309 citations
Semantic Scholar
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
F. André, T. Bachelot, M. Campone, F. Dalenc +12 more
2013Clinical Cancer Research295 citations Open access
Semantic Scholar
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
S. Delaloge, A. Yovine, A. Taamma, M. Riofrio +8 more
2001Journal of Clinical Oncology173 citations
Semantic Scholar
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
A. Psyrri, J. Fayette, K. Harrington, M. Gillison +24 more
2022Annals of Oncology136 citations Open access
Semantic Scholar
A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
L. Zelek, A. Yovine, E. Brain, F. Turpin +5 more
2006British Journal of Cancer93 citations Open access
Semantic Scholar
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
J. Wolf, M. Hochmair, Ji-Youn Han, N. Reguart +22 more
2024The Lancet Oncology82 citations Open access
Semantic Scholar
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
A. Le Cesne, A. Yovine, J. Blay, S. Delaloge +6 more
2012Investigational new drugs82 citations
Semantic Scholar
Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
G. Konecny, T. Kolarova, N. O'Brien, B. Winterhoff +14 more
2013Molecular Cancer Therapeutics74 citations
Semantic Scholar
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
Dong-Wan Kim, R. Mehra, D. Tan, E. Felip +16 more
201470 citations
Semantic Scholar
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
F. Goldwasser, M. Gross-Goupil, J. M. Tigaud, M. di Palma +5 more
2000Annals of Oncology53 citations Open access
Semantic Scholar
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.
P. Viens, T. Petit, A. Yovine, P. Bougnoux +7 more
2006Annals of Oncology45 citations Open access
Semantic Scholar
Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.
H. Richly, T. Kim, M. Schuler, Dong-Wan Kim +5 more
2015Blood44 citations Open access
Semantic Scholar
1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.
A. Shaw, R. Mehra, D. Tan, E. Felip +16 more
2014Annals of Oncology39 citations Open access
Semantic Scholar
1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.
E. Felip, D.-W. Kim, R. Mehra, D. Tan +16 more
2014Annals of Oncology35 citations Open access
Semantic Scholar
A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.
F. André, T. Bachelot, M. Campone, F. Dalenc +9 more
2011Journal of Clinical Oncology33 citations
Semantic Scholar
Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients
J. Alexandre, E. Raymond, M. O. Kaci, E. Brain +9 more
2004Clinical Cancer Research32 citations
Semantic Scholar
Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from the phase 1 , multicentre , open-label ASCEND-1 trial
Dong-Wan Kim, R. Mehra, D. Tan, E. Felip +18 more
201626 citations
Semantic Scholar
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.
Weimin Li, S. Wildsmith, Jia-Bu Ye, H. Si +15 more
202025 citations
Semantic Scholar
Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer
T. Petit, A. Benider, A. Yovine, P. Bougnoux +9 more
2006Anti-Cancer Drugs24 citations
Semantic Scholar
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
S. Wildsmith, Weimin Li, Song Wu, R. Stewart +21 more
2023Clinical Cancer Research19 citations Open access
Semantic Scholar
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
D. Tan, Dong-Wan Kim, Michael Thomas, Serafino Pantano +14 more
201617 citations
Semantic Scholar
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
G. Melillo, V. Chand, A. Yovine, A. Gupta +1 more
2021Advances in Therapy15 citations Open access
Semantic Scholar
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer
T. Delozier, J. Guastalla, A. Yovine, C. Lévy +8 more
2006Anti-Cancer Drugs15 citations
Semantic Scholar
Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma
R. Arends, Xiang Guo, P. Baverel, I. González-García +4 more
2021Oncoimmunology14 citations Open access
Semantic Scholar
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas
R. Salazar, R. Plummer, A. Oaknin, A. Robinson +5 more
2011Investigational new drugs13 citations Open access
Semantic Scholar
Predictive Biomarkers and Personalized Medicine Targeting FGFR with Dovitinib ( TKI 258 ) : Preclinical and Clinical Data in Breast Cancer
F. Andr, T. Bachelot, M. Campone, F. Dalenc +13 more
201312 citations
Semantic Scholar
Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.
D. Tan, A. Shaw, R. Mehra, E. Felip +16 more
201411 citations
Semantic Scholar
Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule
A. Le Cesne, Misset Jl, G. Demetri, J. López-Martín +8 more
200111 citations
Semantic Scholar
26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1
J. Wolf, E. Garon, H. Groen, D. Tan +5 more
2022Annals of Oncology10 citations Open access
Semantic Scholar
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
J. Gornet, Daniel Azoulay, Francis Lévi, A. Yovine +2 more
2000Anti-Cancer Drugs10 citations
Semantic Scholar
LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
E. Garon, S. Lu, Y. Goto, P. D. de Marchi +11 more
2022Annals of Oncology9 citations Open access
Semantic Scholar
Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.
Yi-Long Wu, Ji-Youn Han, T. Kato, F. Barlesi +8 more
2022Journal of Clinical Oncology8 citations
Semantic Scholar
Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone.
T. Herzog, J. Vermorken, E. Pujade-Lauraine, J. Li +4 more
2009Journal of Clinical Oncology8 citations
Semantic Scholar
Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations
J. Bruce, David Geary, B. de las Heras, A. Soto +5 more
20088 citations
Semantic Scholar
Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) inplatinum + taxanes sensitive advanced ovarian cancer (AOC) patients: Final results.
P. Viens, T. Petit, A. Yovine, P. Bougnoux +6 more
2004Journal of Clinical Oncology8 citations
Semantic Scholar
Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors.
A. Cioffi, A. Lecesne, J. Blay, S. Delaloge +5 more
2009Journal of Clinical Oncology7 citations
Semantic Scholar
QTc Monitoring During a Phase I Study: Experience With SR271425
J. Soria, V. Diéras, V. Girre, A. Yovine +2 more
2007American Journal of Clinical Oncology7 citations
Semantic Scholar
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
S. Tagawa, O. Sartor, J. Piulats, Fred Saad +23 more
2026The Lancet5 citations
Semantic Scholar
Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
Dae-Ho Lee, Hye Ryun Kim, B. Keam, Ken Kato +5 more
2023Cancer Medicine5 citations Open access
Semantic Scholar
A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors.
T. Delaunoit, Eric Raymond, A. Awada, F. Savinelli +4 more
2006Journal of Clinical Oncology4 citations
Semantic Scholar
Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer.
V. Pierre, Xiang Guo, I. González-García, N. Morsli +5 more
20203 citations
Semantic Scholar
Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).
G. Demetri, J. Blay, P. Schöffski, R. Maki +6 more
20103 citations
Semantic Scholar
A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer
G. Konecny, N. Finkler, P. Lee, A. Yovine +4 more
20122 citations
Semantic Scholar
434 First-in-man phase I study of PM01183 using an accelerated titration design
M. Ratain, M. E. Elez, S. Szyldergemajn, David Geary +5 more
20102 citations
Semantic Scholar
9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age
G. Demetri, J. Blay, A. Yovine, I. Judson +6 more
20092 citations
Semantic Scholar
Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules
E. Raymond, S. Dueland, M. Lind, A. Awada +6 more
20052 citations
Semantic Scholar
74TiP Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC
Y.-L. Wu, Jy Han, T. Kato, F. Barlesi +8 more
2022Annals of Oncology1 citations Open access
Semantic Scholar
269 Tumoral and peripheral landscape of Viral- versus Carcinogen-Driven Head and Neck Cancer
Tze-Heng Tan, S. Sridhar, H. Angell, E. V. Jones +8 more
20201 citations Open access
Semantic Scholar
Elisidepsin
C. Coronado, C. Galmarini, V. Alfaro, A. Yovine
2020Definitions1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Solomon×8
Invite
B. Solomon — researcher profile on SciRah
A. Shaw×8
Invite
A. Shaw — researcher profile on SciRah
R. Mehra×7
Invite
R. Mehra — researcher profile on SciRah
D. Tan×7
Invite
D. Tan — researcher profile on SciRah

×7

Invite

E. Felip — researcher profile on SciRah

Invite

L. Chow — researcher profile on SciRah

J. Vansteenkiste×7

Invite

J. Vansteenkiste — researcher profile on SciRah

Invite

M. Schuler — researcher profile on SciRah

Dong-Wan Kim×6

Invite

Dong-Wan Kim — researcher profile on SciRah

Invite

D. Camidge — researcher profile on SciRah

Invite

T. De Pas — researcher profile on SciRah

Gregory Riely×6

Invite

Gregory Riely — researcher profile on SciRah